Genmab A-S Aktie
| 192,60EUR | -1,45EUR | -0,75% |
WKN: 565131 / ISIN: DK0010272202
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 94,99 |
| Wellington Management Co. LLP | 4,89 |
| Genmab A/S | 4,04 |
| Vanguard International Growth Fund | 3,20 |
| Vanguard Health Care Fund | 2,50 |
| Government Pension Fund - Global (The) | 2,36 |
| Vanguard Total International Stock Index Fund | 1,36 |
| Jan G. J. van de Winkel, PhD | 0,91 |
| Vanguard Developed Markets Index Fund | 0,84 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 548 | 781 | 1 212 | 1 660 | 2 204 |
| Umsatz pro Mitarbeiter in Mio. EUR | 9,79 | 12,95 | 7,00 | 8,79 | 7,47 |
Bilanz (in Mio. DKK) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 13 961 | 18 791 | 22 736 | 28 377 | 33 139 |
| Summe Anlagevermögen | 1 183 | 2 352 | 1 891 | 1 901 | 2 150 |
| Summe Aktiva | 15 144 | 21 143 | 24 627 | 30 278 | 35 289 |
Bilanz (in Mio. DKK) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 181 | 319 | 425 | 597 | 770 |
| Summe Fremdkapital | 1 096 | 2 022 | 2 431 | 2 837 | 3 679 |
| Summe Eigenkapital | 14 048 | 19 121 | 22 196 | 27 441 | 31 610 |
| Summe Passiva | 15 144 | 21 143 | 24 627 | 30 278 | 35 289 |
Adresse
| Carl Jacobsens Vej 30, 2500 Copenhagen | |
| Internet | http://www.genmab.com |
Management
|
Anders Gersel Pedersen
Non-Independent Director |
|
Andrew Carlsen
Vice President & Head-Investor Relations |
|
Anthony Pagano
Chief Financial Officer & Executive Vice President |
|
Birgitte Stephensen
Chief Legal Officer & Executive Vice President |
|
Brad Bailey
Chief Commercial Officer & Executive VP |
|
Christopher Cozic
Chief People Officer & Executive Vice President |
|
Deirdre P. Connelly
Chairman |
|
Elizabeth G. O'Farrell
Independent Director |
|
Jan G. J. van de Winkel
President & Chief Executive Officer |
|
Judith Klimovsky
Chief Development Officer & Executive VP |
|
Marisol Peron
SVP-Global Communications & Corporate Affairs |
|
Martin Schultz
Non-Independent Director |
|
Martine J. van Vugt
Chief Strategy Officer & Executive Vice President |
|
Mijke Zachariasse
Non-Independent Director |
|
Paolo Augusto Paoletti
Independent Director |
|
Pernille Lyngvold Erenbjerg
Deputy Chairman |
|
Rayne Waller
Chief Technology Officer & Executive VP |
|
Rolf K. Hoffmann
Independent Director |
|
Tahamtan Ahmadi
Chief Medical Officer & Executive Vice President |
|
Takahiro Hamatani
Non-Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
